Header Logo

Connection

Yehuda Handelsman to Pyrans

Back to Details
This is a "connection" page, showing publications Yehuda Handelsman has written about Pyrans.
Yehuda Handelsman
Connection Strength
0.556
Pyrans
  1. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017 10; 33(10):1861-1868.
    View in: PubMed
    Score: 0.556
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.